Termination of Royalty Payments. LICENSEE’s obligation to pay royalties for use of the LICENSED TECHNOLOGY under this Agreement shall terminate in the event LICENSEE pays to LICENSOR a one-time royalty termination payment of ten million ($10,000,000) dollars.
Termination of Royalty Payments. Notwithstanding any provision to the contrary in this License, the Licensor shall not be entitled to receive any royalties under Section 3.2 in respect of any period after the earlier of (a) the termination of this License pursuant to Section 11 hereof or (b) the Technology Transfer Date.
Termination of Royalty Payments. 2.5.4.1 In the event that either U.S. Patent No. 5,016,009 or 4,701,745 is declared invalid or rendered unenforceable, after a final judgment or reexamination and exhaustion of all appeals therefrom, any remaining Microsoft payments due under Section 2.5.1 shall be reduced by ten percent (10%) for each patent so declared invalid or rendered unenforceable as of the time of such final judgement or reexamination and exhaustion of all appeals.
Termination of Royalty Payments. 26 3.8.5 Minimum Royalty Payment for Hectorol(TM)..................................................27 3.8.6 Additional Royalty Payment for Alertec(R).................................................28 3.9
Termination of Royalty Payments. The Purchaser's obligation to pay the Vendor the royalties contemplated in Section 3.8.1 for each Royalty Product shall terminate on a Royalty Product-by-Royalty Product basis on the earliest of:
Termination of Royalty Payments. Licensee’s obligation to pay royalties for use of the Licensed Technology under this Agreement shall terminate upon the Effective Date of this Agreement subject to payments due under Paragraph 2 hereof.
Termination of Royalty Payments. LG Chem shall pay royalties to TBC in accordance with this Section 5.2 as long as Valid Patents protecting the Products are in force. Prior to United States patent expiration protecting the Products, TBC and LG Chem will negotiate in good faith a reduced royalty schedule, if required, relating to continued sales of Products by LG Chem in the Territory.
Termination of Royalty Payments. Subject to Sections 5.2 ([***]), 5.3 ([***]) and 5.4 ([***]), the obligations of Alvotech to pay royalties under this Section 5 shall terminate with respect to a Licensed Indication on the termination date with respect to such Licensed Indication set forth below (the “Royalty Termination Date”): Licensed Indication Royalty Termination Date [***] June 5, 2022 [***] April 11, 2025 [***] June 3, 2031 Upon the Royalty Termination Date with respect to a Licensed Indication, the licenses granted under Section 5.1 with respect to such Licensed Indication will be deemed fully paid up and irrevocable. For clarity, on a Territory-by-Territory and Licensed Indication-by-Licensed Indication basis, Alvotech’s royalty obligation will terminate prior to the Royalty Termination Date only if no Valid [***] Patent Rights, no Valid [***] Patent Rights or no Valid [***] Patent Rights, respectively, remain.
Termination of Royalty Payments. All royalty and similar arrangements between GDS and any Related Party have been terminated and are of no force or effect.
Termination of Royalty Payments. The obligations of Alvotech to pay royalties under this Section 5 shall terminate on the earlier of (i) February 11, 2025; or (ii) a decision by the United States Court of Appeals for the Federal Circuit holding that all unexpired claims of each of the Licensed Humira Patents are invalid or unenforceable (the “Royalty Termination Date”), at which time the non-exclusive, non-transferable (except as permitted by Sections 9.2, 9.3 and 9.5) license granted hereunder will be deemed fully paid up and irrevocable.
